Format

Send to

Choose Destination
BMC Res Notes. 2014 Jan 30;7:65. doi: 10.1186/1756-0500-7-65.

Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China.

Author information

1
Departments of Neurology, Peking Union Medical College Hospital, and Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Wanfujing, Beijing 100730, China. wuzhangzhenxin@medmail.com.cn.

Abstract

BACKGROUND:

Little is known about the clinical features and treatment of Chinese patients with Parkinson disease (PD).

METHODS:

A large cross-sectional survey of clinical features, medication use, and motor complications was conducted in 901 consecutive PD patients, from 42 randomly selected university-affiliated hospitals in four urban economic regions of China, between December 2006 and May 2007.

RESULTS:

The 901 PD patients had age range 30 to 88, and median disease duration 50 months. Most (737, 81.8%) used L-dopa (median 375 mg/day), and often added low doses of other antiparkinsonian agents. Among L-dopa-treated patients, the prevalence of motor complications was low (dyskinesias: 8.5%; motor fluctuations: 18.6%), even among patients with disease duration ≥11 years (dyskinesias: 18.1%; motor fluctuations: 42.2%). Higher L-dopa use was associated with higher occurrence of dyskinesias (OR 2.44; 95% CI 1.20-5.13) and motor fluctuations (OR 2.48; 95% CI 1.49-4.14). Initiating PD treatment with L-dopa alone (OR 0.46; 95% CI 0.22-0.95) or in combination with other medications (OR 0.41; 95% CI 0.19-0.87) was associated with less dyskinesia than treatment initiated with non-L-dopa medication.

CONCLUSIONS:

Many Chinese PD patients are treated with low-dose L-dopa and added low-dose antiparkinsonian agents, with a low prevalence of motor complications, which might be influenced by Chinese culture.

PMID:
24476129
PMCID:
PMC3928922
DOI:
10.1186/1756-0500-7-65
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center